Merck is hoping NanoString's multiplex platform can support gene expression signatures that will better predict which patients will respond to checkpoint inhibitors like its Keytruda.
Cyclica will soon begin testing a commercial version of its services software this summer ahead of a full launch planned for next year.
The company is recruiting patients with TRK fusions and different cancer types in a Phase II basket trial that may pave the way for a "molecular label" for its drug.
The company is working on a bespoke pharmacovigilance product that will leverage its biomedical content, and has added an NGS module to Pathway Studio.
The collaboration will focus on identifying new signaling pathways and targets involved in coronary artery disease.
The Associated Press reports that the US Food and Drug Administration approved 45 new drugs last year.
The partners will focus on developing gene editing-based treatments for cystic fibrosis and sickle cell disease, among other diseases.
Therapies aimed at drug targets that have been linked genetically to disease fare better through the drug development pipeline, researchers from GSK and elsewhere found.
The partners will provide drug discovery services, expertise, and infrastructure in a new AMRI center located in the Buffalo Medical Innovation and Commercialization Hub.
The partners will develop novel drug candidates based on an activated kinase target for an unnamed rare genetic disease.
Researchers suggest that genetic variations could influence the side effects people experience when using synthetic cannabinoids, the International Business Times reports.
An analysis has examined the makeup of researchers on Twitter and what they share, Nature News reports.
At Stat News, Jim Kozubek argues that the Broad Institute is pushing the boundary of what a nonprofit is.
In PNAS this week: gut microbes may affect honeybee weight, phenotype and gene expression changes in DiGeorge syndrome, and more.